Friday, May 20, 2022 8:14:35 AM
IHL-42X is a fixed dose combination of dronabinol and acetazolamide that is being developed as a treatment for obstructive sleep apnoea ('OSA') in adults. Incannex submitted a pre-IND meeting package and meeting request to the FDA in February 2022. The meeting package included an overview of the development program, and specific questions Incannex had on the regulatory requirements for opening an investigational new drug ('IND') application. Opening an IND is required to conduct clinical trials in the U.S and ensures that trials are designed so that they meet the data requirements necessary for FDA marketing approval.
Recent IXHL News
- Incannex Healthcare Inc. Quarterly Update, Q1 2024 • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder • GlobeNewswire Inc. • 02/28/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 01:00:11 PM
- Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation • GlobeNewswire Inc. • 02/16/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 11:16:51 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 12:30:16 PM
- Clarion Clinics Open for Psychedelic-Assisted Treatments • GlobeNewswire Inc. • 02/01/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 09:30:18 PM
- Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis • GlobeNewswire Inc. • 01/24/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 02:08:33 PM
- Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences • GlobeNewswire Inc. • 01/18/2024 01:22:34 PM
- Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea • GlobeNewswire Inc. • 01/17/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 11:05:45 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 11:07:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 01:54:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 01:53:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 01:50:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 01:47:51 AM
- Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia • GlobeNewswire Inc. • 12/21/2023 09:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/20/2023 10:05:54 PM
- Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea • GlobeNewswire Inc. • 12/06/2023 12:30:00 PM
- Incannex Healthcare Announces Completion of its Redomiciliation to the United States • GlobeNewswire Inc. • 11/29/2023 06:40:29 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/16/2023 02:38:31 PM
- Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASIC • GlobeNewswire Inc. • 11/16/2023 01:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/08/2023 11:07:04 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM